Importantly, the STING agonist also altered cell viability in breast cancer organoid model when combined with the BH3 mimetic ABT-737 (Fig. 7j) and decreased tumor progression particularly in combination with Navitoclax in the in vivo MDA-MB-231 xenograft model (Fig. 7k). Here, STING1 is linked to breast carcinoma.